As the next round of Medicare drug pricing negotiations get underway, experts predict President Trump may seek to weaken the program.
Despite online claims, President Donald Trump’s executive orders did not include removing Medicare’s $35 monthly ...
Viking Therapeutics, Inc. offers promising advances in obesity and liver diseases, despite a recent stock drop over GLP-1 market concerns. Click for my VKTX update.
When investors are paying such high price tags for a stock, expectations are high, and any kind of miss can result in a steep ...
Democrat U.S. Senators Urge President Trump to Reject Big Pharma’s Push to End Medicare Price Negotiations, Protect Medicare Enrollees ...
Biotech and pharma dealmaking is off to a good start in 2025. Meanwhile, digital health fundraising defined by “David and ...
A group of lawmakers are urging President Donald Trump to reject pharmaceutical companies’ efforts to pause the Biden administration’s drug-price cuts.
Just how much Medicare price negotiations will negatively impact Novo Nordisk, though, depends on what the final negotiated ...
Medicare drug plans can now cover Eli Lilly & Co.’s obesity drug Zepbound as a treatment for obstructive sleep apnea, news that’s expected to prove a big boost for the drug company.
Shelby Knowles / Bloomberg via Getty Images Eli Lilly's Zepbound can be covered by Medicare Part D plans after the FDA approved the drug as a treatment for sleep apnea last month. Weight loss ...